0
Editorials |

Thrombotic End Point for Assessing Argatroban Therapy for Heparin-Induced Thrombocytopenia: Learning From Secondary Analyses of Prospective Studies

Theodore W. Warkentin, MD
Author and Funding Information

Affiliations: Hamilton, ON, Canada
 ,  Dr. Warkentin is Professor, Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University; is Associate Head of Transfusion Medicine, Hamilton Regional Laboratory Medicine Program; and is a Hematologist at Hamilton Health Sciences (Hamilton General Site).

Correspondence to: Theodore W. Warkentin, MD, Room 1-180A, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (Hamilton General Site), 237 Barton St E, Hamilton, ON, L8L 2X2, Canada; e-mail: twarken@mcmaster.ca



Chest. 2006;129(6):1396-1398. doi:10.1378/chest.129.6.1396
Text Size: A A A
Published online

Extract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder for which relatively few alternative anticoagulants have undergone prospective evaluation as therapeutic agents. Accordingly, one seeks to learn as much as possible from those studies that have been performed. In this issue of CHEST (see page 1407), Lewis and colleagues1 report a secondary analysis of the prospective cohort studies23 of argatroban that led to regulatory approval of this direct thrombin inhibitor (DTI) for the treatment of HIT with or without thrombosis. Should we pay attention to secondary analyses of prospective studies? Yes.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543